About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker JNJ · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult…
NCT04513912 · Depressive Disorder, Major
Seltorexant, Matching placebo to Seltorexant
JNJ
Janssen Research & Development, LLC
Phase 3Completed757Oct 3, 2023Registry ↗
Nov 12, 2026INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock W…
NCT06965504 · Heart Failure, Cardiogenic Shock
Impella 5.5 SmartAssist
JNJ
Abiomed Inc.
Not applicableRecruiting250Dec 1, 2028Registry ↗
Nov 12, 2026Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969 · Sjogrens Syndrome
Nipocalimab, Placebo
JNJ
Janssen Research & Development, LLC
Phase 3Active, not recruiting655Feb 4, 2027Registry ↗
Nov 12, 2026Abiomed Impella RT-DAQ - Observational Study
NCT06308055 · Cardiogenic Shock
Data Acquisition
JNJ
Abiomed Inc.
—Recruiting125Jun 30, 2027Registry ↗
Nov 12, 2026REDUCER-I: An Observational Study of the Neovasc Reducer™ System
NCT02710435 · Angina Pectoris, Angina Pectoris, Stable
Reducer System
JNJ
Shockwave Medical, Inc.
—Active, not recruiting400Nov 2023Registry ↗
Nov 9, 2026A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus…
NCT07735793 · Urinary Bladder Neoplasms
JNJ
Janssen Korea, Ltd., Korea
—Recruiting
was not yet recruiting
1Nov 23, 2026Registry ↗
Nov 6, 2026Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal
NCT07788521 · Visual Acuity
Senofilcon A, Nelfilcon A
JNJ
Johnson & Johnson Vision Care, Inc.
Not applicableRecruiting150Dec 11, 2026Registry ↗
Nov 5, 2026A Study of HARMONIC 700 Shears With Advanced Hemostasis in Pediatric and Adult Surgical Procedures
NCT06608485 · Pediatric Surgical Procedures, Adult Surgical Procedures
HARMONIC 700 Shears
JNJ
Ethicon Endo-Surgery
—Completed173Jun 30, 2026Registry ↗
Nov 5, 2026A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
NCT04968912 · Sjogren's Syndrome
Placebo, Nipocalimab
JNJ
Janssen Research & Development, LLC
Phase 2Completed163Oct 23, 2023Registry ↗
Nov 5, 2026A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622 · Myasthenia Gravis
Nipocalimab, Placebo
JNJ
Janssen Research & Development, LLC
Phase 3Recruiting199Nov 17, 2023Registry ↗
Nov 5, 2026A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
NCT04619420 · Alzheimer Disease, Cognitive Dysfunction
JNJ-63733657, Placebo
JNJ
Janssen Research & Development, LLC
Phase 2Terminated523Oct 17, 2025Registry ↗
Nov 4, 2026A Study to Assess Pregnancy, Neonatal and Infant Outcomes in Participants Exposed to Nipocalimab
NCT07915232 · Pregnancy Related, Pregnancy
JNJ
Janssen Research & Development, LLC
—Not yet recruiting162Apr 30, 2036Registry ↗
Nov 4, 2026A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalid…
NCT07903272 · Multiple Myeloma
Ramantamig, Daratumumab
JNJ
Janssen Research & Development, LLC
Phase 3Not yet recruiting1,000Jan 11, 2037Registry ↗
Nov 4, 2026A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With TRUPULSE™ Generator in Persistent At…
NCT07845682 · Atrial Fibrillation
Radiofrequency/Pulsed Field Ablation
JNJ
Biosense Webster, Inc.
Not applicableRecruiting
was not yet recruiting
150Apr 17, 2028Registry ↗
Nov 4, 2026A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With the TRUPULSE™ Generator for Treatmen…
NCT07727057 · Arrhythmias, Cardiac
Radiofrequency/Pulsed Field Ablation System
JNJ
Biosense Webster, Inc.
Not applicableRecruiting90Sep 30, 2027Registry ↗
Nov 4, 2026A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized S…
NCT07511166 · Atrial Fibrillation
JNJ
Johnson & Johnson Medical (Shanghai) Ltd.
—Recruiting
was not yet recruiting
300Jul 28, 2028Registry ↗
Nov 4, 2026A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants Wi…
NCT07429214 · Atrial Fibrillation
Pulsed Field Ablation System
JNJ
Biosense Webster, Inc.
Not applicableActive, not recruiting42Dec 30, 2026Registry ↗
Nov 4, 2026A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation…
NCT07227532 · Atrial Fibrillation
Pulsed Field Ablation by VARIPULSE Catheter with TRUPULSE G…
JNJ
Biosense Webster, Inc.
Not applicableRecruiting276Dec 31, 2030Registry ↗
Nov 4, 2026A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
NCT07116525 · Scar-related Atrial Tachycardia, Persistent Atrial Fibrilla…
Paddle-Shaped, High-Density, Multi-Electrode Mapping Cathet…
JNJ
Biosense Webster, Inc.
Not applicableRecruiting90Feb 7, 2027Registry ↗
Nov 4, 2026Evaluation of Daily Disposable Toric Soft Lenses Manufactured With an Alternative Hydration Process
NCT06967129 · Astigmatism
Investigational daily disposable, soft, toric lenses manufa…
JNJ
Johnson & Johnson Vision Care, Inc.
Not applicableCompleted281Jul 14, 2025Registry ↗
Nov 4, 2026A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509 · Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B…
JNJ-75348780, JNJ-67856633
JNJ
Janssen Research & Development, LLC
Phase 1Enrolling by invitation120Jan 19, 2028Registry ↗
Nov 4, 2026Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over One Wee…
NCT06749496 · Astigmatism
Test Lens, Control Lens
JNJ
Johnson & Johnson Vision Care, Inc.
Not applicableCompleted134Mar 20, 2025Registry ↗
Nov 4, 2026EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
NCT06631638 · Osteoarthritis, Traumatic Arthritis
EMPHASYS Cup with VHN
JNJ
DePuy Orthopaedics
Not applicableRecruiting118Dec 31, 2027Registry ↗
Nov 4, 2026The Study is an Observational Post-market Follow-up Program to Evaluate Long Term (5 Years) Safety…
NCT06510205 · Breast Augmentation, Mammaplasty
Mentor Breast implants
JNJ
Johnson & Johnson Medical (Shanghai) Ltd.
—Recruiting6,111Jun 30, 2034Registry ↗
Nov 4, 2026A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis…
NCT06220604 · Plaque Psoriasis
JNJ-77242113, JNJ-77242113 Matching Placebo
JNJ
Janssen Research & Development, LLC
Phase 3Active, not recruiting731Nov 15, 2024Registry ↗
Nov 4, 2026A Study of JNJ-87890387 for Advanced Solid Tumors
NCT06178614 · Neoplasms, Advanced Solid Tumors
JNJ-87890387
JNJ
Janssen Research & Development, LLC
Phase 1Recruiting200Mar 16, 2027Registry ↗
Nov 4, 2026A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplas…
NCT06150157 · Neoplasms
JNJ-88549968, Ruxolitinib
JNJ
Janssen Research & Development, LLC
Phase 1Recruiting300Jun 14, 2027Registry ↗
Nov 4, 2026A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878 · Plaque Psoriasis
JNJ-77242113, JNJ-77242113 Matching Placebo
JNJ
Janssen Research & Development, LLC
Phase 3Active, not recruiting774Sep 17, 2024Registry ↗
Nov 4, 2026A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psorias…
NCT06095115 · Plaque Psoriasis
JNJ-77242113, Placebo
JNJ
Janssen Research & Development, LLC
Phase 3Active, not recruiting684Jul 29, 2024Registry ↗
Nov 4, 2026A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or C…
NCT05572515 · Multiple Myeloma
Teclistamab, Pomalidomide
JNJ
Janssen Research & Development, LLC
Phase 3Active, not recruiting614Oct 13, 2025Registry ↗
Nov 4, 2026A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510 · Colitis, Ulcerative
Guselkumab Dose 1, Guselkumab Dose 2
JNJ
Janssen Research & Development, LLC
Phase 3Active, not recruiting418Apr 2, 2024Registry ↗
Nov 4, 2026A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
NCT05379634 · Myositis
Nipocalimab, Placebo
JNJ
Janssen Research & Development, LLC
Phase 2Completed
was active, not recruiting
36Sep 4, 2025Registry ↗
Nov 4, 2026A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
NCT05265273 · Myasthenia Gravis
Nipocalimab
JNJ
Janssen Research & Development, LLC
Phase 2/3Recruiting12Jun 30, 2027Registry ↗
Nov 4, 2026A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Sev…
NCT05242484 · Colitis, Ulcerative
Guselkumab, Golimumab
JNJ
Janssen Research & Development, LLC
Phase 2Active, not recruiting577May 15, 2025Registry ↗
Nov 4, 2026A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Sev…
NCT05242471 · Crohn's Disease
Guselkumab, Golimumab
JNJ
Janssen Research & Development, LLC
Phase 2Active, not recruiting703May 23, 2025Registry ↗
Nov 4, 2026A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With…
NCT04988295 · Carcinoma, Non-Small-Cell Lung
Lazertinib, Amivantamab
JNJ
Janssen Research & Development, LLC
Phase 3Active, not recruiting776Jul 10, 2023Registry ↗
Nov 4, 2026A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098 · Arthritis, Psoriatic
Guselkumab, Placebo
JNJ
Janssen Research & Development, LLC
Phase 3Active, not recruiting1,054Dec 30, 2024Registry ↗
Nov 4, 2026A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560 · Acute Leukemia
Bleximenib
JNJ
Janssen Research & Development, LLC
Phase 1/2Recruiting420Dec 29, 2028Registry ↗
Nov 4, 2026A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acet…
NCT04497844 · Prostatic Neoplasms
Niraparib+ Abiraterone acetate fixed dose combination (FDC)…
JNJ
Janssen Research & Development, LLC
Phase 3Active, not recruiting696Jan 7, 2025Registry ↗
Nov 4, 2026A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or…
NCT04487080 · Carcinoma, Non-Small-Cell Lung
Amivantamab, Osimertinib
JNJ
Janssen Research & Development, LLC
Phase 3Active, not recruiting1,074Aug 11, 2023Registry ↗
Nov 4, 2026A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive S…
NCT04325828 · Salivary Gland Neoplasms
Apalutamide, GnRH Agonist
JNJ
Janssen Pharmaceutical K.K.
Phase 2Active, not recruiting31Jun 9, 2021Registry ↗
Nov 4, 2026A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445 · Ulcerative Colitis
Placebo, Guselkumab
JNJ
Janssen Research & Development, LLC
Phase 2/3Active, not recruiting1,064Sep 19, 2023Registry ↗
Nov 3, 2026A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
NCT07906717 · Prostatic Neoplasms
JNJ-101556143, Placebo
JNJ
Janssen Research & Development, LLC
Phase 3Recruiting
was not yet recruiting
400Feb 14, 2028Registry ↗
Nov 3, 2026A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea
NCT07890285 · Pulmonary Arterial Hypertension
JNJ
Janssen Korea, Ltd., Korea
—Not yet recruiting333Oct 29, 2032Registry ↗
Nov 3, 2026A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease…
NCT07848737 · Colitis, Ulcerative, Crohn Disease
JNJ
Janssen-Cilag, S.A.
—Not yet recruiting200Jun 30, 2029Registry ↗
Nov 3, 2026A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
NCT07832292 · Prostatic Neoplasms
JNJ-101556143
JNJ
Janssen Research & Development, LLC
Phase 2Recruiting100May 17, 2029Registry ↗
Nov 3, 2026A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory Bowel Disease
NCT07822529 · Inflammatory Bowel Diseases
JNJ
Janssen Research & Development, LLC
—Recruiting400Jan 1, 2030Registry ↗
Nov 3, 2026Evaluation of Approved Contact Lenses (CR-6657)
NCT07819305 · Visual Acuity
Test (Senofilcon A), Control (Serafilcon A)
JNJ
Johnson & Johnson Vision Care, Inc.
Not applicableActive, not recruiting
was recruiting
145Dec 3, 2026Registry ↗
Nov 3, 2026A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With t…
NCT07788989 · Atrial Fibrillation
VARIPULSE Catheter System (PVI), VARIPULSE Catheter System…
JNJ
Biosense Webster, Inc.
Not applicableNot yet recruiting2,300Oct 31, 2029Registry ↗
Nov 3, 2026A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis…
NCT07746765 · Crohn Disease, Colitis, Ulcerative
JNJ
Janssen Sciences Ireland UC
—Not yet recruiting35Aug 3, 2029Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:02 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances